A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...
The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...
The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent ...
Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...
The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ...
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...
The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive ...
Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has ...
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer ...
The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a ...
The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results